A Phase I/II Study of OCU400
Latest Information Update: 12 Jan 2022
At a glance
- Drugs OCU 400 (Primary)
- Indications Retinal disorders
- Focus Adverse reactions; Therapeutic Use
- 06 Jan 2022 According to an Ocugen media release, this trial is expected to initiate in Q1 2022.
- 13 Aug 2021 New trial record
- 06 Aug 2021 According to an Ocugen media release, this trial is expected to begin in 2022.